The estimated Net Worth of Taylor Sandison is at least $4.86 Milhão dollars as of 11 March 2024. Taylor Sandison owns over 20,662 units of Cidara Therapeutics Inc stock worth over $4,033,244 and over the last 15 years he sold CDTX stock worth over $55,283. In addition, he makes $774,086 as Chief Medical Officer at Cidara Therapeutics Inc.
Sign up
Taylor Sandison CDTX stock SEC Form 4 insiders trading
Taylor has made over 6 trades of the Cidara Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 20,662 units of CDTX stock worth $13,844 on 11 March 2024.
The largest trade he's ever made was selling 20,662 units of Cidara Therapeutics Inc stock on 11 March 2024 worth over $13,844. On average, Taylor trades about 4,797 units every 118 days since 2010. As of 11 March 2024 he still owns at least 347,095 units of Cidara Therapeutics Inc stock.
You can see the complete history of Taylor Sandison stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Taylor Sandison biography
Dr. Taylor Sandison M.D. serves as Chief Medical Officer of the Company. Prior to joining the Company, he served as senior medical director at Merck and prior to that held the same position at Cubist Pharmaceuticals, Inc. Dr. Sandison has also held positions at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, M.D. and M.P.H. degrees from the University of Washington, and a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine. He completed internal medicine residency training at the University of Colorado and infectious diseases fellowship training at the University of Washington. Dr. Sandison currently holds board certifications in Infectious Diseases and Internal Medicine.
What is the salary of Taylor Sandison?
As the Chief Medical Officer of Cidara Therapeutics Inc, the total compensation of Taylor Sandison at Cidara Therapeutics Inc is $774,086. There are 3 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.
How old is Taylor Sandison?
Taylor Sandison is 48, he's been the Chief Medical Officer of Cidara Therapeutics Inc since 2017. There are 14 older and 3 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
What's Taylor Sandison's mailing address?
Taylor's mailing address filed with the SEC is C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR, STE 101, SAN DIEGO, CA, 92121.
Insiders trading at Cidara Therapeutics Inc
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio..., eSteve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
What does Cidara Therapeutics Inc do?
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
What does Cidara Therapeutics Inc's logo look like?
Complete history of Taylor Sandison stock trades at Cidara Therapeutics Inc
Cidara Therapeutics Inc executives and stock owners
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Stein,
President, Chief Executive Officer, Director -
Dr. Jeffrey L. Stein Ph.D.,
Pres, CEO & Exec. Director -
Neil Abdollahian,
Chief Business Officer -
Taylor Sandison,
Chief Medical Officer -
Paul Daruwala,
Chief Operating Officer -
Dr. Taylor Sandison,
Chief Medical Officer -
Daniel Burgess,
Independent Chairman of the Board -
Theodore Schroeder,
Independent Director -
Chrysa Mineo,
Independent Director -
Timothy Franson,
Independent Director -
David Gollaher,
Independent Director -
Robert Uhl,
IR Contact Officer -
Jessica Oien,
General Counsel, Secretary -
James Levine,
Chief Financial Officer -
Dr. Kenneth F. Bartizal Ph.D.,
Chief Devel. Officer -
Allison Lewis CCP, SPHR,
VP of HR -
Shane M. Ward,
Chief Legal Officer & Corp. Sec. -
Christopher A. Kurtz,
Exec. VP of Technical Operations -
Brady Johnson,
Principal Accounting Officer, Controller & VP of Fin. -
Paul Daruwala,
COO & Chief Commercial Officer -
Dr. Preetam Shah M.B.A., Ph.D.,
CFO & Chief Bus. Officer -
Dr. Kevin M. Forrest Ph.D.,
Founder and Chief Strategy Officer -
Robert J Perez,
Director -
Scott M Rocklage,
Director -
Ken Bartizal,
Chief Development Officer -
Matthew Onaitis,
Gnrl Counsel, CFO & Secretary -
Marc Wilson,
Chief Accounting Officer -
Dirk Thye,
Chief Medical Officer -
Kevin Forrest,
COO & CFO -
Laura Tadvalkar,
Director -
Preetam Shah,
CFO & CBO -
Target N Vbb Biotech Ag Bio...,
-
Patrick J Heron,
Director -
Nina S Kjellson,
Director -
Steve Elms,
Director -
Bonnie L Bassler,
Director -
Carin Canale Theakston,
Director -
Leslie Tari,
CHIEF SCIENTIFIC OFFICER -
Brady Johnson,
Vice President, Finance -
Shane Ward,
COO & CLO -
Ryan Spencer,
Director -
James Merson,
Director -
Capital Management, L.P.Ra ...,